The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...

2 Typically, carcinoid syndrome is characterized ... chemotherapeutic agents most widely used to treat metastatic neuroendocrine tumors. Our experience suggests that fluoropyrimidines and ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

The approval came on the bases of the results from the phase 3 CABINET study. The study compared cabozantinib to a placebo in ...

Carcinoid tumor of midgut origin with large ... flushing and upper abdominal pain was referred to the neuroendocrine tumor unit by his oncologist. He had experienced a weight loss of 10 kg over ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine ...

Clinical Director of the Gastrointestinal Cancer Center and Director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute. “This FDA approval marks a meaningful ...

After 1 month, the facial erythema had markedly reduced. Carcinoid tumors are neoplasms that arise from neuroendocrine cells throughout the body, but are most prevalent in the gastrointestinal ...

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo ...